A proof of concept study of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Oxytocin (Primary)
Indications Binge-eating disorder; Diabetes mellitus; Glucose intolerance; Insulin resistance; Migraine; Obesity; Pain; Prader-Willi syndrome
Focus Proof of concept; Therapeutic Use

31 May 2023 According to a Tonix Pharmaceuticals media release, TNX-2900 has been granted Orphan Drug designation by the FDA.
29 May 2023 New trial record
22 May 2023 According to a Tonix Pharmaceuticals media release, the company has collaborated with Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology, Erasmus University Medical Center for this study. He will sever as principal investigator for the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com